NasdaqGS:REGNBiotechs
Did Disappointing Trial Data Amid Strong Dupixent and Eylea Sales Just Shift Regeneron’s (REGN) Investment Narrative?
Regeneron Pharmaceuticals recently faced a setback after disappointing clinical trial results for one of its pipeline drugs, even as key products Dupixent and Eylea continued to perform well and the company pursued share repurchases.
This contrast between a strong track record in marketed therapies and weaker near-term pipeline readouts has shifted investor attention toward questions about the company’s future innovation cadence.
We’ll now examine how concern over weaker near-term pipeline...